Zimu Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zimu Deng has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Anthony K. Shum
Cardiovascular Research Institute, University of California, San Francisco (C.S.L., A.K.S.).
1 shared publication Bradley J. Backes
Department of Medicine, University of California, San Francisco, San Francisco, CA 1
1 shared publicationChristopher S. Law
Department of Medicine, University of California, San Francisco, San Francisco, CA 1
1 shared publicationFrances O. Ho
Department of Medicine, University of California, San Francisco, San Francisco, CA 1
1 shared publication- Kojiro Mukai
Laboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Tohoku University, Sendai, Japan
1 shared publication Tereza Martinu
Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, Ontario, Canada 3
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 28 July 2020
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 217 (11)
A defect in COPI-mediated transport of STING causes immune dysregulation in COPA syndrome
Pathogenic COPA variants cause a Mendelian syndrome of immune dysregulation with elevated type I interferon signaling. COPA is a subunit of coat protein complex I (COPI) that mediates Golgi to ER transport. Missense mutations of the COPA WD40 domain impair binding and sorting of proteins targeted for ER retrieval, but how this causes disease remains unknown. Given the importance of COPA in Golgi–ER transport, we speculated that type I interferon signaling in COPA syndrome involves missorting of STING. We show that a defect in COPI transport causes ligand-independent activation of STING. Furthermore, SURF4 is an adapter molecule that facilitates COPA-mediated retrieval of STING at the Golgi. Activated STING stimulates type I interferon–driven inflammation in CopaE241K/+ mice that is rescued in STING-deficient animals. Our results demonstrate that COPA maintains immune homeostasis by regulating STING transport at the Golgi. In addition, activated STING contributes to immune dysregulation in COPA syndrome and may be a new molecular target in treating the disease.
- 28 July 2020
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 217 (11)
Top Cited PapersOpen AccessA defect in COPI-mediated transport of STING causes immune dysregulation in COPA syndrome
Pathogenic COPA variants cause a Mendelian syndrome of immune dysregulation with elevated type I interferon signaling. COPA is a subunit of coat protein complex I (COPI) that mediates Golgi to ER transport. Missense mutations of the COPA WD40 domain impair binding and sorting of proteins targeted for ER retrieval, but how this causes disease remains unknown. Given the importance of COPA in Golgi–ER transport, we speculated that type I interferon signaling in COPA syndrome involves missorting of STING. We show that a defect in COPI transport causes ligand-independent activation of STING. Furthermore, SURF4 is an adapter molecule that facilitates COPA-mediated retrieval of STING at the Golgi. Activated STING stimulates type I interferon–driven inflammation in CopaE241K/+ mice that is rescued in STING-deficient animals. Our results demonstrate that COPA maintains immune homeostasis by regulating STING transport at the Golgi. In addition, activated STING contributes to immune dysregulation in COPA syndrome and may be a new molecular target in treating the disease.